INO
Inovio Pharmaceuticals, Inc.
There isn't enough reported data to score INO yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
INO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
INO's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
INO PE Valuation
INO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
INO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect INO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
INO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.67 | +$1.88 |
| Q2 2026 | -$1.04 | +$1.53 |
| Q1 2026 | -$1.58 | +$1.57 |
| Q4 2025 | -$1.81 | +$2.14 |
| Q3 2025 | -$2.55 | +$1.89 |
| Q2 2025 | -$2.57 | +$2.54 |
| Q1 2025 | -$3.15 | +$2.33 |
| Q4 2024 | -$3.95 | +$2.14 |
INO is still losing money, but far less than before: $0.67 per share over the past year, against $20.64 at its worst in mid-2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over INO on earnings quality, reporting a profit while its opponent remains loss making.
INO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $117K | +14% |
| Q2 2024 | $100.8K | -55% |
| Q4 2023 | $102.7K | -18% |
| Q3 2023 | $388.4K | -96% |
| Q2 2023 | $226K | -71% |
| Q1 2023 | $114.9K | -42% |
| Q4 2022 | $124.7K | -85% |
| Q3 2022 | $9.2M | +3038% |
INO's revenue is growing: $298,901 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6532% | N/A |
| Q1 2025 | -38337% | N/A |
| Q4 2024 | -17411% | +9276 points |
| Q2 2024 | -32946% | -16554 points |
| Q4 2023 | -26686% | +18191 points |
| Q3 2023 | -9153% | -8762 points |
| Q2 2023 | -16392% | -3116 points |
| Q1 2023 | -38238% | -2205 points |
INO's operating margin was −6532% last quarter, up 20154 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over INO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over INO on profitability, with a higher operating margin.
INO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$6.4M |
| Q2 2026 | -$18M | +$2.8M |
| Q1 2026 | -$21.6M | +$5.3M |
| Q4 2025 | -$19.5M | +$165.9K |
| Q3 2025 | -$21.6M | +$5.8M |
| Q2 2025 | -$20.8M | +$7.8M |
| Q1 2025 | -$26.9M | +$1.9M |
| Q4 2024 | -$19.7M | +$6.6M |
INO has burned cash in almost every quarter: −$74M over the past year, against −$89M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over INO on cash generation, producing positive trailing cash flow while its opponent burns cash.
INO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +17M shares |
| 1 year | +154% | +59.8M shares |
| 3 years | +358% | +77.1M shares |
| 5 years | +485% | +81.8M shares |
INO has 99M diluted shares, up 154% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over INO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INO Net Leverage
INO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
INO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.5 | Neutral |
| Stochastic | 32.9 | Neutral |
INO's weekly RSI is 57 (neutral) and its Stochastic is 33 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
INO PE vs Healthcare Sector
INO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
INO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 35% above |
| 20 week MA | $1.10 | 33% above |
| 50 week MA | $1.35 | 8.1% above |
| 100 week MA | $1.67 | 13% below |
| 200 week MA | $4.98 | 71% below |
INO has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 71% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over INO on trend strength, trading above more of its moving averages.
INO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.1 | $123.1 | +207% |
| 2021 | $123.1 | $73.0 | -41% |
| 2022 | $73.0 | $18.4 | -75% |
| 2023 | $18.4 | $6.12 | -67% |
| 2024 | $6.12 | $1.87 | -69% |
| 2025 | $1.87 | $2.29 | +22% |
| 2026 YTD | $2.29 | $1.46 | -36% |
INO's yearly returns have swung widely, from +207% in 2020 to −75% in 2022. It's down 36% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over INO on returns for 2026, with the stronger performance.